Which COVID vaccine works best? new study pits novavax against pfizer
NCT ID NCT07287137
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compares how well two FDA-approved COVID-19 vaccines—Novavax (a protein-based vaccine) and Pfizer (an mRNA vaccine)—trigger the immune system. Researchers will measure antibody levels against several virus variants in 54 healthy adults aged 18-79 who have risk factors for severe COVID. The goal is to see which vaccine offers stronger and broader protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Novavax recombinant protein COVID-19 vaccine and Pfizer-BioNTech mRNA COVID-19 vaccine
- What this could lead to
- If successful, this study could help determine which COVID-19 vaccine type provides stronger or broader immune protection against current and future variants.
- What could go wrong
- This is a small, early-stage comparison study (54 participants) focused on immune markers, not clinical outcomes like preventing infection. Results may not apply to the general population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Walter Reed National Military Medical Center
Bethesda, Maryland, 20814, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?